Research Papers

25 of 163 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the t…
Zhou YB; Zhang YM; Huang HH; Shen LJ; Han XF; Hu XB; Yu SD; Gao AH; Sheng L; Su MB; Wei XL; Zhang Y; Zhang YF; Gao ZW; Chen XY; Nan FJ; Li J; Hou J.
Acta Pharmacol Sin (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates.
Wang Y; Fang S; Wu Y; Cheng X; Zhang LK; Shen XR; Li SQ; Xu JR; Shang WJ; Gao ZB; Xia BQ.
Acta Pharmacol Sin (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therap…
Zhang F; Liu W; Huang J; Chen QL; Wang DD; Zou LW; Zhao YF; Zhang WD; Xu JG; Chen HZ; Ge GB.
Acta Pharmacol Sin (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
ATF3 contributes to brucine-triggered glioma cell ferroptosis via promotion of hydrogen peroxide and iron.
Lu S; Wang XZ; He C; Wang L; Liang SP; Wang CC; Li C; Luo TF; Feng CS; Wang ZC; Chi GF; Ge PF.
Acta Pharmacol Sin (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Mitochondrial proteome of mouse oocytes and cisplatin-induced shifts in protein profile.
Zhang N; Sun AD; Sun SM; Yang R; Shi YY; Wang QL; Li XY; Ma JH; Yue W; Xie BT; Qiao J; Li M.
Acta Pharmacol Sin (Unknown)
Published: 2021
3/6 Transparent
Data Funding Declared
Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combin…
Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM.
Acta Pharmacol Sin (Unknown)
Published: 2021
2/6 Transparent
Cinnamaldehyde induces autophagy-mediated cell death through ER stress and epigenetic modification in gastric cancer ce…
Kim TW.
Acta Pharmacol Sin (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
The glycolytic process in endothelial cells and its implications.
Leung SWS; Shi Y.
Acta Pharmacol Sin (Unknown)
Published: 2021
1/6 Transparent
Natural products: potential treatments for cisplatin-induced nephrotoxicity.
Fang CY; Lou DY; Zhou LQ; Wang JC; Yang B; He QJ; Wang JJ; Weng QJ.
Acta Pharmacol Sin (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, C…
Liu XQ; Xue S; Xu JB; Ge H; Mao Q; Xu XH; Jiang HD.
Acta Pharmacol Sin (Unknown)
Published: 2021
2/6 Transparent
Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial act…
Zhang JD; Liu J; Zhu SW; Fang Y; Wang B; Jia Q; Hao HF; Kao JY; He QH; Song LJ; Liu F; Zhu BL; Owyang C; Duan LP.
Acta Pharmacol Sin (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Rictor/mTORC2 involves mitochondrial function in ES cells derived cardiomyocytes via mitochondrial Connexin 43.
Wang JD; Shao Y; Liu D; Liu NY; Zhu DY.
Acta Pharmacol Sin (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a prop…
Zou H; Li SQ.
Acta Pharmacol Sin (Unknown)
Published: 2020
1/6 Transparent
Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphos…
Hu WJ; Chang L; Yang Y; Wang X; Xie YC; Shen JS; Tan B; Liu J.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Zhang XL; Li ZM; Ye JT; Lu J; Ye LL; Zhang CX; Liu PQ; Duan DD.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.
Su HX; Yao S; Zhao WF; Li MJ; Liu J; Shang WJ; Xie H; Ke CQ; Hu HC; Gao MN; Yu KQ; Liu H; Shen JS; Tang W; Zhang LK; Xiao GF; Ni L; Wang DW; Zuo JP; Jiang HL; Bai F; Wu Y; Ye Y; Xu YC.
Acta Pharmacol Sin (Unknown)
Published: 2020
3/6 Transparent
Data Funding Declared
Mitochondrial Ca<sup>2+</sup> regulation in the etiology of heart failure: physiological and pathophysiological implica…
Xu HX; Cui SM; Zhang YM; Ren J.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Phase separation as a therapeutic target in tight junction-associated human diseases.
Sun S; Zhou J.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Fisetin alleviates sepsis-induced multiple organ dysfunction in mice via inhibiting p38 MAPK/MK2 signaling.
Zhang HF; Zhang HB; Wu XP; Guo YL; Cheng WD; Qian F.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
Pang X; Cui Y; Zhu Y.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Cancer nanomedicine meets immunotherapy: opportunities and challenges.
Sun Q; Bai X; Sofias AM; van der Meel R; Ruiz-Hernandez E; Storm G; Hennink WE; De Geest B; Kiessling F; Yu HJ; Lammers T; Shi Y.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism.
Ryan AT; Pulukuri AJ; Davaritouchaee M; Abbasi A; Hendricksen AT; Opp LK; Burt AJ; Nielsen AE; Mancini RJ.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ.
Acta Pharmacol Sin (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung …
Zhang LL; Lu J; Liu RQ; Hu MJ; Zhao YM; Tan S; Wang SY; Zhang B; Nie W; Dong Y; Zhong H; Zhang W; Zhao XD; Han BH.
Acta Pharmacol Sin (Unknown)
Published: 2020
3/6 Transparent
Data Funding Declared